Ausgabe 4/2023
Inhalt (18 Artikel)
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
- editorial
Gabriel Rinnerthaler
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
- short review
Patrick Reimann, Thomas Winder
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma
- Open Access
- short review
Angela Djanani
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
- Open Access
- short review
Aysegül Ilhan-Mutlu, Ewald Wöll
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
- case report
Sophie Roider-Schur, Sybille Machat, Leopold Öhler
Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
- comment
Isabel Heidegger, Andreas Pircher
Focal therapy in intermediate- and high-risk prostate cancer
- Open Access
- short review
Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
- Open Access
- short review
Sazan Rasul, Stephan Korn
Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors
- Open Access
- short review
Petar Popov
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
- Open Access
- short review
Ronald Heregger, Richard Greil
Management of malignant hypercalcemia in cancer patients—a short review
- short review
Clemens Petrasch, Petra Marics, Thomas Spanberger
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
- original report
Manal Atef, Layla M. Saleh, Noha Eisa, Sameh Shamaa
